This event will examine whether or not Medicare can meet its obligations to seniors despite rapidly rising health costs and shrinking revenues.

The lesson from the Scott McClellanstory is not that presidents should seek staffers even more fanatically loyal than Bush's, but that weak personalities break under pressure.

While controversy has raged over the Food and Drug Administration’s (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA’s role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

While controversy has raged over the Food and Drug Administration's (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA's role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

At this event, John A. Vernon and Joseph H. Golec will discuss their new AEI Press book.

At a December 11 conference that focused on the policies of the FDA, AEI resident fellow Scott Gottlieb argued the need for change in the agency's drug-approval guidelines.

The U.S. health system is recognized as the world's leader in clinical innovation, yet millions of Americans do not have health insurance, reducing their access to those life-enhancing and life-saving treatments. AEI has invited twenty academic experts from around the country as well as members of the...

While the FDAneeds tochange to respond to innovations in cancer therapies, regulators must maintain safeguards on drug approval.